Stock Market & Financial Investment News

News Breaks December 20, 2012 20:08 EDT HEB Hemispherx fatigue drug Ampligen rejected for approval, WSJ reports An FDA panel voted 8-to-5 against approval of Hemixpherx's (HEB) chronic fatigue drug Ampligen at an FDA Arthritis Advisory Committee Meeting Thursday, according to a Wall Street Journal report. Reference Link News For HEB From The Last 14 Days Check below for free stories on HEB the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. There are no results for HEB Sign up for a free trial to see the rest of the stories you've been missing.